Regeneron, the masters of antibody development and cell surface tech, is going inside the cell. And they’ve chosen the RNAi leaders at Alnylam to lead them in — with some very big goals in mind.
The numbers involved in this new, largely preclinical pact are blockbuster proportioned. And that is very rare.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,300+ biopharma pros who read Endpoints News by email every day.Free Subscription